A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
Bromodomain-containing protein 4 (BRD4) is a key protein that drives the development of malignant melanoma and is closely associated with the ferroptosis signaling pathway. Degradation of BRD4 can downregulate the expression of ferroptosis-related genes such as GPX4, thereby promoting tumor-specific...
Saved in:
Main Authors: | Linghong Huang, Xinyuan Sun, Qinhua Zuo, Ting Song, Ning Liu, Zonghua Liu, Wei Xue |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-04-01
|
Series: | Materials Today Bio |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S259000642500081X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PROTAC-based therapeutics for targeting HPV oncoproteins in head and neck cancers
by: Nobendu Mukerjee, et al.
Published: (2025-12-01) -
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01) -
PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01) -
ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2
by: Dan Li, et al.
Published: (2025-01-01) -
Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination
by: Katja Uršič Valentinuzzi, et al.
Published: (2025-02-01)